Journal of Surgical Research
Volume 140, Issue 1 , Pages 55-66 , 1 June 2007

Estrogen Receptor β/α Ratio Predicts Response of Pancreatic Cancer Cells to Estrogens and Phytoestrogens

  • Srivani Konduri, Ph.D.
    • ,
  • Roderich E. Schwarz, M.D., Ph.D.

      Affiliations

    • Corresponding Author InformationTo whom correspondence and reprint requests should be addressed at Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901.

Received 7 August 2006

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA-Cancer J Clin. 2006;56:106
  2. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10
  3. Fong Y, Gonen M, Rubin D, et al. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg. 2005;242:540
  4. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403
  5. Andren-Sandberg A, Hoem D, Backman PL. Other risk factors for pancreatic cancer: hormonal aspects. Ann Oncol. 1999;10(Suppl 4):131
  6. Schwarz RE, Donohue CA, Sadava D, et al. Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: Implications for monotherapy and combination treatment. Cancer Lett. 2003;189:59
  7. Greenway B, Iqbal MJ, Johnson PJ, et al. Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J (Clin Res Ed). 1981;283:751
  8. Pousette A, Carlstrom K, Skoldefors H, et al. Purification and partial characterization of a 17 β-estradiol-binding macromolecule in the human pancreas. Cancer Res. 1982;42:633
  9. Benz C, Hollander C, Miller B. Endocrine-responsive pancreatic carcinoma: Steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res. 1986;46:2276
  10. Poston GJ, Townsend CM, Rajaraman S, et al. Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas. 1990;5:151
  11. Selvan RS, Metzgar RS, Petrow V. Growth modulatory effects of some 6-methylenic steroids on human and hamster pancreatic adenocarcinoma cells in vitro. Drug Des Discov. 1992;9:119
  12. Theve NO, Pousette A, Carlstrom K. Adenocarcinoma of the pancreas—a hormone sensitive tumor? (A preliminary report on Nolvadex treatment). Clin Oncol. 1983;9:193
  13. Wong A, Chan A, Arthur K. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep. 1987;71:749
  14. Keating JJ, Johnson PJ, Cochrane AM, et al. A prospective randomized controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer. 1989;60:789
  15. Wong A, Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas (A case-control study). Cancer. 1993;71:2200
  16. Rosenberg L, Barkun AN, Denis MH, et al. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer. 1995;75:23
  17. Horimi T, Takasaki M, Toki A, et al. The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas. Hepatogastroenterology. 1996;43:1225
  18. Wenger FA, Jacobi CA, Siderow A, et al. Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen. Chirurg. 1999;70:694
  19. Schumacher G, Kataoka M, Roth JA, et al. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res. 1999;5:493
  20. Sumi C, Brinck-Johnsen T, Longnecker DS. Inhibition of a transplantable pancreatic carcinoma by castration and estradiol administration in rats. Cancer Res. 1989;49:6687
  21. Kuramoto M, Yamashita J, Ogawa M. Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells. Cancer. 1995;75:1263
  22. Lhoste EF, Roebuck BD, Brinck-Johnsen T, et al. Effect of castration and hormone replacement on azaserine-induced pancreatic carcinogenesis in male and female Fischer rats. Carcinogenesis. 1987;8:699
  23. Sumi C, Longnecker DS, Roebuck BD, et al. Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in Fischer rats treated with azaserine. Cancer Res. 1989;49:2332
  24. Longnecker DS, Sumi C. Effects of sex steroid hormones on pancreatic cancer in the rat. Int J Pancreatol. 1990;7:159
  25. Abe M, Yamashita J, Ogawa M. Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation. Cancer. 2000;88:2000
  26. Targarona EM, Pons MD, Gonzalez G, et al. Is exocrine pancreatic cancer a hormone-dependent tumor? (A study of the existence of sex hormone receptors in normal and neoplastic pancreas). Hepatogastroenterology. 1991;38:165
  27. Taylor OM, Teasdale J, Cowen PN, et al. Classical oestrogen receptor is not detectable in pancreatic adenocarcinoma. Br J Cancer. 1992;66:503
  28. Ollayos CW, Riordan GP, Rushin JM. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch Pathol Lab Med. 1994;118:630
  29. Adami HO, Persson I, Hoover R, et al. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer. 1989;44:833
  30. Baum A, Kamino K, Son WC, et al. Lack of influence of diethylstilbestrol on induced pancreatic ductal carcinomas in Syrian hamsters. Exp Toxicol Pathol. 1995;47:117
  31. Wenger FA, Kilian M, Mautsch I, et al. Influence of octreotide and tamoxifen on tumor growth and liver metastasis in N-nitroso-bis(2-oxopropyl)amine-induced pancreatic cancer in Syrian hamsters. Horm Res. 2000;54:74
  32. Crowson MC, Dorrell A, Rolfe EB, et al. A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma. Eur J Surg Oncol. 1986;12:335
  33. Swarovsky B, Wolf M, Havemann K, et al. Tamoxifen or cyproterone acetate in combination with buserelin are ineffective in patients with pancreatic adenocarcinoma. Oncology. 1993;50:226
  34. Bakkevold KE, Pettersen A, Arnesjo B, et al. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg. 1990;77:725
  35. Taylor OM, Benson EA, McMahon MJ The Yorkshire Gastrointestinal Tumor Group. Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. Br J Surg. 1993;80:384
  36. Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription and transactivation: Estrogen receptor α and estrogen receptor β: Regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res. 2000;2:335
  37. Friess H, Buchler M, Kiesel L, et al. LH-RH receptors in the human pancreas (Basis for antihormonal treatment in ductal carcinoma of the pancreas). Int J Pancreatol. 1991;10:151
  38. Singh S, Baker PR, Poulsom R, et al. Expression of estrogen receptor and estrogen-inducible genes in pancreatic cancer. Br J Surg. 1997;84:1085
  39. Hollande E, Fanjul M, Houti N, et al. Expression of estrogen receptors during growth of human pancreatic adenocarcinoma cells (Capan-1)-relationship with differentiation. In Vitro Cell Dev Biol Anim. 1998;34:593
  40. Iwao K, Miyoshi Y, Ooka M, et al. Quantitative analysis of estrogen receptor-α and -β messenger RNA expression in human pancreatic cancers by real-time polymerase chain reaction. Cancer Lett. 2001;170:91
  41. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology. 1998;139:4252
  42. An J, Tzagarakis-Foster C, Scharschmidt TC, et al. Estrogen receptor β-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem. 2001;276:17808
  43. Roger P, Sahla ME, Makela S, et al. Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res. 2001;61:2537
  44. Knowlden JM, Gee JM, Robertson JF, et al. A possible divergent role for the estrogen receptor α and β subtypes in clinical breast cancer. Int J Cancer. 2000;89:209
  45. Cullen R, Maguire TM, McDermott EW, et al. Studies on estrogen receptor-α and -β mRNA in breast cancer. Eur J Cancer. 2001;37:1118
  46. Dotzlaw H, Leygue E, Watson PH, et al. Estrogen receptor-β messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins. Cancer Res. 1999;59:529
  47. Jarvinen TA, Pelto-Huikko M, Holli K, et al. Estrogen receptor β is coexpressed with ERα and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol. 2000;156(1):29–35
  48. Leygue E, Dotzlaw H, Watson PH, et al. Expression of estrogen receptor β1, β2, and β5 messenger RNAs in human breast tissue. Cancer Res. 1999;59:1175
  49. Speirs V, Malone C, Walton DS, et al. Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 1999;59:5421
  50. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERβ isoforms in colon cancer. Cancer Res. 2001;61:632
  51. Foley EF, Jazaeri AA, Shupnik MA, et al. Selective loss of estrogen receptor β in malignant human colon. Cancer Res. 2000;60:245
  52. Fiorelli G, Picariello L, Martineti V, et al. Functional estrogen receptor β in colon cancer cells. Biochem Biophys Res Commun. 1999;261:521
  53. Arai N, Strom A, Rafter JJ, et al. Estrogen receptor β mRNA in colon cancer cells: Growth effects of estrogen and genistein. Biochem Biophys Res Commun. 2000;270:425
  54. Latil A, Bieche I, Vidaud D, et al. Evaluation of androgen, estrogen (ER α and ER β), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 2001;61:1919
  55. Ito T, Tachibana M, Yamamoto S, et al. Expression of estrogen receptor (ER-α and ER-β) mRNA in human prostate cancer. Eur Urol. 2001;40:557
  56. Leav I, Lau KM, Adams JY, et al. Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol. 2001;159:79
  57. Lau KM, LaSpina M, Long J, et al. Expression of estrogen receptor (ER)-α and ER-β in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res. 2000;60:3175
  58. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U.S.A. 1999;96:5722
  59. Pujol P, Rey JM, Nirde P, et al. Differential expression of estrogen receptor-α and -β messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res. 1998;58:5367
  60. Utsunomiya H, Suzuki T, Harada N, et al. Analysis of estrogen receptor α and β in endometrial carcinomas: correlation with ER β and clinicopathologic findings in 45 cases. Int J Gynecol Pathol. 2000;19:335
  61. Omoto Y, Kobayashi Y, Nishida K, et al. Expression, function, and clinical implications of the estrogen receptor β in human lung cancers. Biochem Biophys Res Commun. 2001;285:340
  62. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem. 2001;17:17
  63. Jones PS, Parrott E, White IN. Activation of transcription by estrogen receptor α and β is cell type- and promoter-dependent. J Biol Chem. 1999;274:32008
  64. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor β acts as a dominant regulator of estrogen signaling. Oncogene. 2000;19:4970
  65. Hall JM, McDonnell DP. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology. 1999;140:5566
  66. Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science. 1997;277:1508
  67. Katzenellenbogen BS, Choi I, Delage-Mourroux R, et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol. 2000;74:279
  68. Dutertre M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther. 2000;295:431
  69. Balabhadrapathruni S, Thomas TJ, Yurkow EJ, et al. Effects of genistein and structurally related phytoestrogens on cell cycle kinetics and apoptosis in MDA-MB-468 human breast cancer cells. Oncol Rep. 2000;7:3
  70. Morito K, Hirose T, Kinjo J, et al. Interaction of phytoestrogens with estrogen receptors α and β. Biol Pharm Bull. 2001;24:351
  71. Lyn-Cook BD, Stottman HL, Yan Y, et al. The effects of phytoestrogens on human pancreatic tumor cells in vitro. Cancer Lett. 1999;142:111
  72. Bausero P, Ben-Mahdi M, Mazucatelli J, et al. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. Am J Physiol Heart Circ Physiol. 2000;279:H2033
  73. Curtis SW, Washburn T, Sewall C, et al. Physiological coupling of growth factor and steroid receptor signaling pathways: Estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc Natl Acad Sci U.S.A. 1996;93:12626

PII: S0022-4804(06)00537-3

doi: 10.1016/j.jss.2006.10.015

Journal of Surgical Research
Volume 140, Issue 1 , Pages 55-66 , 1 June 2007

Article Tools

* Image Usage & Resolution